东阳光药业递交上市申请 抗感染药物领域表现突出

Core Viewpoint - Dongyang Sunshine Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with CICC serving as the sole sponsor [1] Group 1: Company Overview - Established in 2003, Dongyang Sunshine Pharmaceutical is a comprehensive pharmaceutical company engaged in drug research and development, production, and commercialization [1] - The company focuses on innovative drugs, improved new drugs, generic drugs, and biosimilars, primarily targeting infection, chronic diseases, and tumors [1] - Dongyang Sunshine has a leading R&D platform, international standard production facilities, and a global sales network [1] Group 2: Research and Development - As of June 30, 2024, the company has 147 approved drugs globally and over 100 drugs in development, including 45 first-class innovative drugs [1] - Dongyang Sunshine is one of the few Chinese pharmaceutical companies that have successfully launched a first-class innovative drug through independent R&D and has three first-class innovative drugs under application for listing [1] Group 3: Market Performance - The company has shown strong performance in the anti-infection drug sector, with its product Kewi R (Oseltamivir Phosphate) capturing 64.8% of the Oseltamivir market in China in 2023 [1] - Dongyang Sunshine possesses a vast sales network covering China, Europe, and North America [1]